Propeptide of lysyl oxidase for treatment of cancer
AssigneesYeda Research and Development Co. Ltd., Ramot at Tel-Aviv University Ltd.
InventorsIrit SAGI, Nikolaos A. AFRATIS, Inna SOLOMONOV, Carmit LEVY, Shivang PARIKH
Life of this patent
Estimating the term…
Abstract
A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.
Claims20
A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70), the method comprising administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM, thereby treating the cancer.
An article of manufacture comprising:
- (i) a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM;
- and
- (ii) an immune modulating agent.
Dependencies are inferred from the claim text.